Evaluation Questions
1. Use the following CASE to answer questions 1 through 3.
A. Ramucirumab
B. Pembrolizumab plus lenvatinib
C. Regorafenib
D. Nivolumab
E. Unsure
2. Which of the following is true regarding immune therapy for WM?
A. Nivolumab could be given once every 2 weeks or once every 4 weeks, depending on the dose
B. Immunotherapy has been shown to be superior to other second-line treatment options for aHCC
C. In order to be eligible for nivolumab therapy, WM will need to express high levels of PD1
D. If WM progresses on this treatment, it would be appropriate to add ipilimumab at that time
E. Unsure
3. What should WM be told to expect regarding this treatment?
A. Unlike traditional chemotherapy, immunotherapy has no side effects that could be concerning
B. Respiratory side effects are common, and WM should call his oncologist if he notices a persistent cough or shortness of breath
C. Nivolumab will be administered over 2 hours every 3 weeks
D. Due to the inhibition of T-cell proliferation, WM may be at a higher risk of developing T-cell lymphoma in the future
E. Unsure
4. Use the following CASE to answer questions 4 and 5.
A. Atezolizumab plus bevacizumab
B. Sorafenib
C. Ramucirumab
D. Nivolumab plus ipilimumab
E. Unsure
5. Which of the following is the correct dosing and frequency of ramucirumab?
A. 8 mg/kg intravenously (IV) once weekly until disease progression
B. 8 mg/kg IV every 2 weeks until disease progression
C. 10 mg/kg IV every 3 weeks until disease progression
D. 8 mg/kg by mouth every 2 weeks until disease progression
E. Unsure
6. Use the following CASE to answer questions 6 through 8.
A. PD-1 and c-Met
B. PD-L1 and CTLA-4
C. PD-1 and CTLA-4
D. PD-L1 and VEGF
E. Unsure
7. MD is found to have significant diarrhea during his treatment and is determined to have moderate (grade 2) colitis. Further evaluation is completed and rules out infectious etiologies. What is the appropriate treatment for MD?
A. Reduce his dose of immunotherapy and administer methylprednisolone 1 mg/kg/day
B. Hold immunotherapy and give methylprednisolone 1 mg/kg/day
C. Hold immunotherapy and give loperamide 4 mg by mouth as needed
D. Continue current regimen and add infliximab
E. Unsure
8. After 3 days, MD has not shown a response to methylprednisolone. What is the best next step?
A. Increase methylprednisolone to 2 mg/kg/day
B. Add diphenoxylate and atropine 5 mg by mouth 4 times daily to current treatment
C. Add infliximab 10 mg/kg once
D. Add vedolizumab 300 mg once
E. Unsure
9. Use the following CASE to answer questions 9 and 10.
A. Total-body skin exam
B. Patient history of dermatologic diseases
C. Location and characteristics of the skin irritation
D. All of the above
E. Unsure
10. After the patient is seen in the same-day clinic, it is determined that he has grade 2 pruritus. How should HT be treated?
A. Hold immunotherapy and treat with prednisone 0.5 mg/kg/day
B. Continue immunotherapy, increase antipruritic therapy, add an oral antihistamine, and apply a high-potency topical steroid to the affected areas
C. Hold immunotherapy and get an urgent dermatology consult
D. Continue immunotherapy, add an oral antihistamine, add prednisone 1 mg/kg/day, and consider a dermatology consult
E. Unsure
11. How confident are you in your decision about treatment for WM in the questions above?
A. Not at all confident
B. Somewhat confident
C. Confident
D. Highly confident
12. How confident are you in your decision about treatment for CD in the questions above?
A. Not at all confident
B. Somewhat confident
C. Confident
D. Highly confident
13. How confident are you in your decision about treatment for MD in the questions above?
A. Not at all confident
B. Somewhat confident
C. Confident
D. Highly confident
14. How confident are you in your decision about treatment for HT in the questions above?
A. Not at all confident
B. Somewhat confident
C. Confident
D. Highly confident
